Akari Therapeutics Regains Full Nasdaq Compliance
19. November 2024 08:00 ET
|
Akari Therapeutics Plc
- Shareholders Equity Deficiency has been Cured - - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market - BOSTON and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Akari...
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
14. November 2024 16:15 ET
|
Akari Therapeutics Plc
- Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
08. November 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
15. Oktober 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
17. September 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
19. August 2024 16:15 ET
|
Akari Therapeutics Plc
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology...
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
19. August 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics announced today that the company has received positive and constructive Pre-IND (PIND) feedback from the FDA on July 29, 2024,...
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
05. Juni 2024 08:00 ET
|
Akari Therapeutics Plc
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June...
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
04. Juni 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today...
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
16. Mai 2024 08:00 ET
|
Akari Therapeutics Plc
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer...